Skip to content
Vaccibody becomes Nykode.
Read more
×
Main Navigation
About us
Company profile
Our values
Our strategy
Board of directors
Management
Our history
Innovation and research
Technology platform
Therapeutic areas
Scientific papers and presentations
Pipeline
Partnering
Our approach
Our partnerships
Investors
Financial reports and presentations
Share information
Analyst coverage
Major shareholders
Financial calendar
Corporate governance
Corporate governance statements
ESG
Dividend policy
Annual general meeting
Articles of association
Safe harbour statement
Whistleblower policy
Risk management
Investor relations policy
Email alerting service
Media
News and announcements
Image library
Glossary
Careers
Life at Nykode
Meet us
Open positions
COVID trial
Search
Media
News and Announcements
Newest first
Oldest first
Announcements
News
Search
Reset
28/12/2021
Nykode Therapeutics announces first subject dosed with its T cell focused next-generation SARS-CoV-2 vaccine candidate
15/12/2021
Vaccibody AS – Notice of Extraordinary General Meeting
15/12/2021
New chairman at Nykode Therapeutics as the Company enters a new stage of internationalization
30/11/2021
Minutes of Extraordinary General Meeting
24/11/2021
Nykode Therapeutics (formerly Vaccibody*)) resolves to issue shares to Regeneron
Pages:
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
Last Page
Load more
Sorry, nothing found in this query
Privacy statement
Cookie policy
Disclaimer
Vaccibody becomes Nykode Therapeutics
Having made significant steps forward in our journey of growth and transformation, we are proud to introduce our new name, Nykode Therapeutics, and a powerful new brand identity.
